arrow
E

Enrico N. De Toni

Universität München
H指数:37
被引数:7,288

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Nivolumab in combination with lenvatinib in unresectable hepatocellular carcinoma: the IKF-t006/IMMUNIB translational phase-2 study

纳武利尤单抗联合仑伐替尼治疗不可切除性肝细胞癌:IKF-t006/IMMUNIB转化性Ⅱ期研究

2026-06-030
OAAI
Liver Transplantation After Immune Checkpoint Inhibition in Hepatocellular Carcinoma—Data From the Multinational LITCHI Registry

免疫检查点抑制剂治疗后肝细胞癌患者的肝移植——来自跨国LITCHI登记研究的数据

2026-05-190
OAAI
Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass)

序贯或 upfront 三联疗法(durvalumab、tremelimumab 和 bevacizumab)用于不可切除的肝细胞癌患者的方案:MONTBLANC 试验方案(AIO-HEP-0325/ass)

2026-02-200
PRE
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study

索赔数据能告诉我们关于肝细胞癌患者风险因素和生存情况的信息吗?——来自一项德国基于人群的研究的见解

2025-12-170
OAAI
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study

Schrodi S,Berger-Thürmel K,Becht S,von Bergwelt-Baildon M,Buggisch P,Hofmann WP,等。治疗缺口与肝癌生存结局:一项基于全国性、理赔数据的见解。Ther Adv Med Oncol. (2025) 17:17588359251363202. doi: 10.1177/17588359251363202。

2025-10-180
OA
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity

阿特珠单抗/贝伐珠单抗治疗肝细胞癌的早期死亡率与肝功能受损及全身免疫改变相关

2025-07-010
OAAI
Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance

CDK4/6抑制在结直肠癌中的疗效及p16表达在预测药物抵抗中的作用

2025-06-160
OAAI
Impact of Helicobacter pylori on Immune Checkpoint Inhibition in Hepatocellular Carcinoma: A Multicenter Study
2025-02-190
PRE
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients
2024-08-011
PRE
Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events

阿特珠单抗/贝伐单抗或来伐替尼治疗肝细胞癌: 多中心真实世界研究,重点关注出血和血栓栓塞事件

2024-06-014
OAAI
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

tremelimumab联合durvalumab治疗不可切除肝细胞癌的III期喜马拉雅研究的四年总生存期更新

2024-05-0139
OA